Literature DB >> 14973538

Reduced immunogenicity of DNA vaccine plasmids in mixtures.

M Sedegah1, Y Charoenvit, L Minh, M Belmonte, V F Majam, S Abot, H Ganeshan, S Kumar, D J Bacon, A Stowers, D L Narum, D J Carucci, W O Rogers.   

Abstract

We measured the ability of nine DNA vaccine plasmids encoding candidate malaria vaccine antigens to induce antibodies and interferon-gamma responses when delivered alone or in a mixture containing all nine plasmids. We further examined the possible immunosuppressive effect of individual plasmids, by assessing a series of mixtures in which each of the nine vaccine plasmids was replaced with a control plasmid. Given alone, each of the vaccine plasmids induced significant antibody titers and, in the four cases for which appropriate assays were available, IFN-gamma responses. Significant suppression or complete abrogation of responses were seen when the plasmids were pooled in a nine-plasmid cocktail and injected in a single site. Removal of single genes from the mixture frequently reduced the observed suppression. Boosting with recombinant poxvirus increased the antibody response in animals primed with either a single gene or the mixture, but, even after boosting, responses were higher in animals primed with single plasmids than in those primed with the nine-plasmid mixture. Boosting did not overcome the suppressive effect of mixing for IFN-gamma responses. Interactions between components in a multiplasmid DNA vaccine may limit the ability to use plasmid pools alone to induce responses against multiple targets simultaneously.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14973538     DOI: 10.1038/sj.gt.3302139

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  31 in total

1.  Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer.

Authors:  C Trollet; Y Pereira; A Burgain; E Litzler; M Mezrahi; J Seguin; M Manich; M R Popoff; D Scherman; P Bigey
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

2.  Inclusion of the bovine neutrophil beta-defensin 3 with glycoprotein D of bovine herpesvirus 1 in a DNA vaccine modulates immune responses of mice and cattle.

Authors:  Sarah Mackenzie-Dyck; Jennifer Kovacs-Nolan; Marlene Snider; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Clin Vaccine Immunol       Date:  2014-01-22

3.  Induction of protective immune responses by a multiantigenic DNA vaccine encoding GRA7 and ROP1 of Toxoplasma gondii.

Authors:  Juan-Hua Quan; Jia-Qi Chu; Hassan Ahmed Hassan Ahmed Ismail; Wei Zhou; Eun-Kyeong Jo; Guang-Ho Cha; Young-Ha Lee
Journal:  Clin Vaccine Immunol       Date:  2012-03-14

Review 4.  Genetic vaccination approaches against malaria based on the circumsporozoite protein.

Authors:  Sandra Scheiblhofer; Richard Weiss; Josef Thalhamer
Journal:  Wien Klin Wochenschr       Date:  2006       Impact factor: 1.704

5.  A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP142 in a Prime/Boost Heterologous Immunization Regimen Partially Protects Aotus Monkeys against Blood-Stage Challenge.

Authors:  Nicanor Obaldia; Michael G Stockelman; William Otero; Jennifer A Cockrill; Harini Ganeshan; Esteban N Abot; Jianfeng Zhang; Keith Limbach; Yupin Charoenvit; Denise L Doolan; De-Chu C Tang; Thomas L Richie
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

6.  Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys.

Authors:  Michael S Seaman; Ling Xu; Kristin Beaudry; Kristi L Martin; Margaret H Beddall; Ayako Miura; Anna Sambor; Bimal K Chakrabarti; Yue Huang; Robert Bailer; Richard A Koup; John R Mascola; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

7.  Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites.

Authors:  Masanori Mizutani; Mitsuhiro Iyori; Andrew M Blagborough; Shinya Fukumoto; Tomohiro Funatsu; Robert E Sinden; Shigeto Yoshida
Journal:  Infect Immun       Date:  2014-08-04       Impact factor: 3.441

8.  Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease.

Authors:  Eduardo L V Silveira; Carla Claser; Filipe A B Haolla; Luiz G Zanella; Mauricio M Rodrigues
Journal:  Clin Vaccine Immunol       Date:  2008-06-25

9.  Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA.

Authors:  B Ferraro; K T Talbott; A Balakrishnan; N Cisper; M P Morrow; N A Hutnick; D J Myles; D J Shedlock; N Obeng-Adjei; J Yan; A K K Kayatani; N Richie; W Cabrera; R Shiver; A S Khan; A S Brown; M Yang; U Wille-Reece; A J Birkett; N Y Sardesai; D B Weiner
Journal:  Infect Immun       Date:  2013-07-29       Impact factor: 3.441

10.  Comparative testing of six antigen-based malaria vaccine candidates directed toward merozoite-stage Plasmodium falciparum.

Authors:  David E Arnot; David R Cavanagh; Edmond J Remarque; Alison M Creasey; Mercy P K Sowa; William D Morgan; Anthony A Holder; Shirley Longacre; Alan W Thomas
Journal:  Clin Vaccine Immunol       Date:  2008-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.